Free Biopharma Daily Stock Updates - 06/14/21

$XBI $137 +1%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$NVAX -1% Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously. source

$COCP +10% Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants. source

$MRNA -6% Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland. source

$HGEN -2.8% Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). source

$NVAX -1% Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial. source

Pipeline Updates

$FUSN +0.1% Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434. source

$OMER -2% Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association. source

$VIR +/-0% Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021. source

$EXEL -1% Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors. source

$RAPT +116% RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis. source

$CCCC -0.2% C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies. source

$LPCN +4.5% FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study. source

$JAZZ +0.1% Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community. source

$TERN -12% Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH. source

$GBT -1% GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK. source

$GTHX +5.2% G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer. source

$ATXI -28.2% Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol. source

$ITOS +37.3% iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations. source

$AVXL +35.4% Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease. source

$ALXO +1% ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies. source

$LABP +2% Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients. source

$TERN -12.5% Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH. source

$RAPT +116% RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis. source

$ASND +3.2% Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency. source

Financial Updates

$CCCC -0.2% C4 Therapeutics Launches Proposed Public Offering. source

$PDSB +6.6% PDS Biotech Announces Proposed Offering of Common Stock. source

$RAPT +116% RAPT THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. source

---

Posted by